Black Diamond Therapeutics elects three Class II directors, ratifies PwC

Black Diamond Therapeutics, Inc.

Class II directors elected: Behbahani (14.5M for, 20.0M withheld), Menzel (33.5M for, 0.96M withheld), Kulkarni (14.2M for, 20.3M withheld); 8.5M broker non-votes each.
Ratification of PwC as auditor for FY2025 passed: 42.48M for, 0.45M against, 59k abstain.
Annual meeting held June 12, 2025 with 42.99M shares present out of 56.68M outstanding, establishing quorum.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.